Sökning: onr:"swepub:oai:prod.swepub.kib.ki.se:145621706" >
Cytomegalovirus (CM...
Cytomegalovirus (CMV) Cell-Mediated Immunity and CMV Infection After Allogeneic Hematopoietic Cell Transplantation: The REACT Study
-
Chemaly, RF (författare)
-
El Haddad, L (författare)
-
Winston, DJ (författare)
-
visa fler...
-
Rowley, SD (författare)
-
Mulane, KM (författare)
-
Chandrasekar, P (författare)
-
Avery, RK (författare)
-
Hari, P (författare)
-
Peggs, KS (författare)
-
Kumar, D (författare)
-
Nath, R (författare)
-
- Ljungman, P (författare)
- Karolinska Institutet
-
Mossad, SB (författare)
-
Dadwal, SS (författare)
-
Blanchard, T (författare)
-
Shah, DP (författare)
-
Jiang, Y (författare)
-
Ariza-Heredia, E (författare)
-
visa färre...
-
(creator_code:org_t)
- 2020-02-20
- 2020
- Engelska.
-
Ingår i: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. - : Oxford University Press (OUP). - 1537-6591. ; 71:9, s. 2365-2374
- Relaterad länk:
-
https://academic.oup...
-
visa fler...
-
http://kipublication...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- BackgroundCytomegalovirus (CMV) infection remains an important cause of morbidity and mortality in allogeneic hematopoietic cell transplant (allo-HCT) recipients. CMV cell-mediated immunity (CMV-CMI) as determined by a peptide-based enzyme-linked immunospot (ELISPOT) CMV assay may identify patients at risk for clinically significant CMV infection (CS-CMVi).MethodsThe CS-CMVi was defined as CMV viremia and/or disease necessitating antiviral therapy. CMV-CMI was characterized as high when the intermediate-early 1 (IE-1) antigen spot counts (SPCs) were >100 (cutoff 1) or when the IE-1 and phosphoprotein 65 antigen SPCs were both >100 SPCs per 250 000 cells (cutoff 2), and a low CMV-CMI when SPCs were below these thresholds. In this prospective multicenter study, we evaluated CMV-CMI every 2 weeks from the pretransplant period until 6 months posttransplantation in 241 allo-HCT recipients with positive CMV serostatus. The primary endpoint was CS-CMVi occurring within 2 weeks of the last measurement of CMV-CMI.ResultsCS-CMVi occurred in 70 allo-HCT recipients (29%). CMV-CMI was low in patients who experienced CS-CMVi (94%), whereas those who had a high CMV-CMI were less likely to have CS-CMVi (P < .0001). Patients with CS-CMVi had higher all-cause mortality (P = .007), especially those with low CMV-CMI (P = .035). On multivariable analysis, CMV-CMI, sex, race, antithymocyte globulin, and steroid use were independent predictors of CS-CMVi, and the time from transplant to engraftment was the only predictor of mortality.ConclusionsMeasurement of CMV-CMI using a novel ELISPOT assay would be useful clinically to monitor allo-HCT recipients and distinguish between those at risk of developing CS-CMVi and requiring antiviral prophylaxis or therapy and those who are protected.
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Chemaly, RF
-
El Haddad, L
-
Winston, DJ
-
Rowley, SD
-
Mulane, KM
-
Chandrasekar, P
-
visa fler...
-
Avery, RK
-
Hari, P
-
Peggs, KS
-
Kumar, D
-
Nath, R
-
Ljungman, P
-
Mossad, SB
-
Dadwal, SS
-
Blanchard, T
-
Shah, DP
-
Jiang, Y
-
Ariza-Heredia, E
-
visa färre...
- Artiklar i publikationen
-
Clinical infecti ...
-
Clinical Infecti ...
- Av lärosätet
-
Karolinska Institutet